Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by Wall Street Zen to Hold

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

REGN has been the topic of several other reports. Scotiabank lifted their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. HSBC began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price objective on the stock. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $803.17 on Monday. The firm has a market cap of $84.91 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.16 and a beta of 0.40. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The business’s fifty day simple moving average is $762.17 and its two-hundred day simple moving average is $666.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $12.07 earnings per share. Analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,636 shares of company stock valued at $2,862,920. 7.02% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. CreativeOne Wealth LLC increased its holdings in shares of Regeneron Pharmaceuticals by 17.9% during the 4th quarter. CreativeOne Wealth LLC now owns 782 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 119 shares during the last quarter. Kestra Advisory Services LLC increased its stake in Regeneron Pharmaceuticals by 14.9% during the fourth quarter. Kestra Advisory Services LLC now owns 4,405 shares of the biopharmaceutical company’s stock worth $3,400,000 after acquiring an additional 571 shares during the last quarter. Transamerica Financial Advisors LLC raised its position in Regeneron Pharmaceuticals by 380.0% in the fourth quarter. Transamerica Financial Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 38 shares during the period. Parkside Financial Bank & Trust raised its position in Regeneron Pharmaceuticals by 70.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 278 shares of the biopharmaceutical company’s stock valued at $215,000 after purchasing an additional 115 shares during the period. Finally, 1248 Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $705,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.